Patheon and Procaps S.A. will provide a new line of prescription pharmaceutical soft gel product development and manufacturing services. The offering will be branded as “P-Gels” soft gels and the partnership will give Patheon rights to market Procaps’ soft gel technology and manufacturing capabilities in North America, Europe and Asia.
 
“This exclusive agreement is part of our recently announced strategy to strengthen our core operations and product offerings,” said Jim Mullen, Patheon’s chief executive officer. “By combining Procaps’ manufacturing capabilities and proprietary technology with our global experience, reach and customer service, we are positioned to provide our customers royalty-free soft gel capsule solutions for their products.”
 
“Procaps is pleased to enter into this agreement with Patheon, one of the leading providers of contract development and manufacturing services in the world,” said Ruben Minski, chief executive officer of Procaps. “This partnership truly provides us with a great opportunity to leverage our quality soft gel capabilities across the globe through Patheon’s customers and beyond.”